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USE OF LOBELINE COMPOUNDS IN THE
TREATMENT OF CENTRAL NERVOUS
SYSTEM DISEASES AND PATHOLOGIES

and IWamoto, 1986). Although initially lobeline Was shoWn
to generaliZe to nicotine in discrimination studies (Geller et

al., 1971), most subsequent studies have failed to reproduce

this original ?nding (Schechter and Rosecrans, 1972;
REFERENCE TO RELATED APPLICATION

Reavill et al., 1990; Romano and Goldstein, 1980).
Nicotine has been reported to be avidly self-administered
by rats (Corrigal et al. 1992, 1994; Donny et al., 1996);
hoWever, the ability of lobeline to support self

This application is a continuation-in-part of US. patent
application Ser. No. 08/795,852, ?led Feb. 5, 1997 US. Pat.
No. 5,830,904.
FIELD OF THE INVENTION

10

The present invention relates to the use of lobeline and

analogs thereof in the treatment of diseases and pathologies
of the central nervous system (CNS). The invention also
relates to the treatment of drug abuse and WithdraWal
therefrom, as Well as eating disorders, such as obesity.

15

considered to be a nicotinic agonist (Decker et al., 1995).
The positive reinforcing effect of nicotine is believed to be
due to the activation of central dopaminergic systems

(BoWell and Balfour, 1992; Corrigal et al., 1992, 1994).

BACKGROUND OF THE INVENTION

Lobeline (ot-lobeline) is a lipophilic, non-pyridino, alka
loidal constituent of Indian tobacco (Lobelia in?ata). As
shoWn by the folloWing formulas, no obvious structural
resemblance to S(—)nicotine is apparent:

administration has not been investigated. Based on the
differential effects of lobeline and nicotine in behavioral
studies, it appears that these drugs may not be acting via a
common CNS mechanism, even though lobeline is often

20

Presynaptic nicotinic receptors have been found on dopam
ine (DA)-containing nerve terminals (Giorguieff-Chesselet
et al., 1979; Clarke and Pert, 1985). Nicotine binds to

nicotinic receptors With high affinity (Kd=1—7 nM)
(Lippiello and Fernandes, 1986; Reavill et al., 1988; Romm
et al., 1990; Bhat et al., 1991; Loiacono et al., 1993;
Anderson and Arneric, 1994). Also, lobeline has been

25

reported to displace [3H]nicotine binding from central nico
tinic receptors With high affinity (Ki=5—30 nM) (Yamada et
al., 1985; Lippiello and Fernades, 1986; Banerjee and
Abood, 1989; Broussolle et al., 1989).
Chronic treatment With nicotine results in an increase in

30

35

the number of nicotinic receptors in many regions of rat and
mouse brain (Collins et al., 1990; Bhat et al., 1991, 1994;
Marks et al., 1992; Sanderson et al., 1993). An increase in
the number of nicotinic receptors in postmortem human
brain tissue obtained from smokers also has been reported

(BenWell et al., 1988). In contrast, chronic lobeline admin
istration did not increase the number of nicotinic receptors
in mouse brain regions in Which increases Were observed

folloWing chronic nicotine administration (Bhat et al.,

1991).
Structure-function relationships betWeen nicotine and

40

lobeline do not suggest a common pharmacophore (BarloW

and Johnson, 1989). Nonetheless, lobeline has been reported
to have many nicotine-like effects including tachycardia and

hypertension (Olin et al., 1995), bradycardia and hypoten
sion in urethane and pentobarbital anesthetiZed rats (Sloan et

45

al., 1988), hyperalgesia (Hamann and Martin, 1994), mid
olytic activity (Brioni et al., 1993), and improvement of

1986; Damsma et al., 1989; BraZell et al., 1990; Toth et al,
1992). Nicotine-evoked DA release is calcium-dependent,
mecamylamine-sensitive and mediated by nicotinic recep
tors (Giorguieff-Chesselet et al., 1979; Westfall et al, 1987;
Rapier et al., 1988; Grady et al., 1992). Mecamylamine is a
noncompetitive nicotinic receptor antagonist, Which more
effectively blocks the ion channel of the receptor (Varanda
et al., 1985; Loiacono et al., 1993; Peng et al., 1994). Similar

learning and memory (Decker et al., 1993). Moreover,
lobeline has been used as a substitution therapy for tobacco

smoking cessation (Nunn-Thompson and Simon, 1989;
Prignot, 1989; Olin et al., 1995); hoWever, its effectiveness
is controversial as re?ected by both positive (Dorsey, 1936;

KalyuZhnyy, 1968) and negative reports (Wright and
Littauer, 1937; Nunn-Thompson and Simon, 1989).
Furthermore, only short-term usage of lobeline as a smoking
deterrent has been recommended due to its acute toxicity
(nausea, severe heartburn and diZZiness) and the lack of

55

Based on these neurochemical studies, lobeline Was sug
60

gested to be an agonist at nicotinic receptors (Decker et al.,
1995). It is difficult to reconcile that nicotine and lobeline

similarly release DA and displace [3H]nicotine binding;

locomotor activity (Clarke and Kumar, 1983a, 1983b;
Clarke, 1990; Fung and Lau, 1988), and to produce condi
tioned place preference (Shoaib et al., 1984); Fudala et al.,

hoWever, the observed upregulation of nicotinic receptors
folloWing chronic nicotine administration is not observed

1985) in rats. HoWever, the results of the latter studies are

controversial (Clarke and Fibiger, 1987). In contrast,

to nicotine, lobeline has been reported to increase DA
release from superfused rat and mouse striatal synaptosomes

(Sakurai et al., 1982; Takano et al, 1983; Grady et al., 1992).

information concerning its long-term usage (Wright and
Littauer, 1937; Olin et al., 1995).
In behavioral studies, nicotine has been shoWn to increase

Nicotine evokes DA release in in vitro superfusion studies

using striatal slices (Westfall, 1974; Giorguieff-Chesselet et
al., 1979; Westfall et al., 1987; Harsing et al., 1992) and
striatal synaptosomes (Chesselet, 1984; RoWell et al., 1987;
Rapier et al., 1988, 1990; Grady et al., 1992, 1994; RoWell
and Hillebrand, 1992, 1994; RoWell, 1995), and in in vivo
studies using microdialysis in striatum (Imperato et al.,

65

folloWing chronic lobeline administration.
Earlier studies of the pharmacokinetic properties of

lobeline does not increase locomotor activity (Stolerman et

lobeline have centered on its proposed use in the treatment

al., 1995) or produce conditioned place preference (Fudala

of nicotinism. For example, US. Pat. Nos. 5,536,503; 5,486,

6,087,376
3

4

362; 5,403,595; and PCT Publication WO 92/19241 are all
related to a drug delivery system and method for treating

in treating dependencies on drugs of abuse is implicated by
the present studies. In particular, the treatment of dependen

nicotine dependence. US. Pat. Nos. 5,414,005; 4,971,079;

cies on such drugs as cocaine, amphetamines, caffeine,

and 3,901,248 also discuss the use of lobeline in the context

phencyclidine, opiates, barbiturates, benZodiaZepines,

of treating nicotine abuse and/or addiction. A scienti?c
article has studied the actions of morphine, lobeline, and
other drugs in inducing “analgesia” in rats (S. Hamann et al.
1994). HoWever, these Workers did not equate their ?nding

Also, the treatment of eating disorders, such as obesity, is
implicated. In a preferred aspect of the invention, the

of an “analgesic” response for lobeline to a reduction of the
pain response in man, nor did they propose the use of

cannabinoids, hallucinogens, and alcohol is implicated.
method of treatment reduces an individual’s desire for the
10

lobeline in treating drug abuse, WithdraWal from addiction,
and the like.
Similarly, to the present inventors’ knowledge, the use of
lobeline in the treatment of eating disorders has not been

drug of abuse or for food by at least one day.
A lobeline compound of the present invention is contem
plated primarily for use in the treatment of diseases and

pathologies associated With the CNS. Thus, cognitive
disorders, head or brain trauma, memory loss, psychosis,

sleep disorders, obsessive-compulsive disorders, panic

proposed. This is in spite of the Widely accepted ability of
nicotine to suppress appetite (see, e.g., Remington’s Pharm.
Sci., 18th ed., p.891) and the previously proposed associa
tion of obesity With reduced bioavailability of dopamine
(US. Pat. Nos. 5,552,429; 5,576,321; 5,272,144; and 5,468,

15

755).

20

disorders, myasthenia gravis, Parkinson’s disease, AlZhe
imer’s disease, schiZophrenia, Tourette’s syndrome, Hun
tington’s disease, and attention de?cit disorder, and related
conditions are considered to be susceptible to treatment With

The present study further elucidates the mechanism of

DTBZ),
action ofa structural
lobeline using
analog[3H]dihydrotetrabenaZine
of tetrabenaZine (TBZ), Which
binds to a single class of high-af?nity sites on the vesicular

a lobeline compound of the present invention.
As shoWn by the results of the studies described herein,
and contrary to conventional belief, lobeline is found to act
at higher concentrations primarily not as a nicotinic agonist,
but by a different mechanism than is observed for nicotine.
The present studies also suggest that lobeline may be

effective in inhibiting uptake of extracellular dopamine by
cells of the CNS, perhaps by blocking dopamine receptors

monoamine transporter-2 protein (VMAT2) to inhibit
vesicular DA uptake (Pletscher et al., 1962; Scherman et al.,
1986; Kilbourn et al., 1995; Liu et al., 1996). Of note, TBZ

on the cells. Either or both mechanisms can thereby Work to

does not alter spontaneous efflux of [3H]DA from rat brain

increase the extracellular concentration of dopamine. Many

vesicles (Floor et al., 1995). Taken together, TBZ appears to
block [3H]DA uptake into vesicles but does not promote
[3H]DA release from vesicles.
In the present study, the effect of lobeline is compared
With that of d-amphetamine, a psychostimulant and lipo
philic Weak base reported to inhibit DA uptake into striatal

synaptic vesicles (Philippu and Beyer, 1973; Ary and
Komiskey, 1980) and to inhibit monoamine uptake into
human VMAT2 expressed in CV-1 cells (Erickson et al.,
1996). d-Amphetamine has also been reported to release DA
from synaptic vesicles of the Planorbis corneas giant DA
cell, increasing DA concentrations in the cytosol and pro
moting reverse transport of DA via DAT (SulZer and

Rayport, 1990; SulZer et al., 1995). Furthermore,
d-amphetamine has been reported to inhibit [3H]DTBZ
binding to rat striatal homogenates (Rostene et al., 1992) and
human VMAT2 expresed in COS cells (GonZaleZ et al.,
1994), but With loW potency. The ability of lobeline to evoke
[3H]DA release from rat striatal synaptic vesicles preloaded
With [3H]DA is also assessed in the present study.

respects in Which the actions of lobeline are similar to those

of amphetamine have been identi?ed.
BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B depict the time course of nicotine
35

evoked fractional release (A) and concentration-dependence
of nicotine-evoked total [3H]over?oW (B) from rat striatal

slices preloaded With [3H]DA (3,4-dihydroxyphenylethyl-2
[N-3H]-amine). Nicotine Was added to the superfusion

buffer after the second sample (as indicated by the arroW)
40

and remained in the buffer until the end of the experiment.
The data in FIG. 1A are presented as means:S.E. fractional
release, Which represents the tritium in the sample as a
percentage of the total tritium in the slice at the time of
sample collection. The data in FIG. 1B are presented as

45

mean:S.E. total [3H]over?oW, Which represents the area
under the curve of the corresponding nicotine concentration
response as a function of time. §P<0.05, different from basal

(5—10 min), When fractional release Was collapsed across

nicotine concentration; *P<0.05, signi?cantly different from
0—0.01 pM and 1—100 pM; **P<0.05, different from 0—0.1
pM and 100 pM; ***P<0.05, different from 0—10 pM;
Duncan’s NeW Multiple Range Test. n=4—9 rats.

SUMMARY OF THE INVENTION

The present invention is for a method of treating an
individual Who suffers from a disease or pathology of the

central nervous system (CNS). The method comprises
administering to the individual an amount of a lobeline 55

compound, i.e., lobeline, analogs, and derivatives thereof,

FIGS. 2A and 2B depict the time course of lobeline
evoked fractional release from rat striatal slices preloaded
With [3H]DA. Lobeline Was added to the superfusion buffer

after the collection of the second sample (as indicated by the

including pharmaceutically acceptable salts. The amount of

arroW) and remained in the buffer until the end of the

lobeline compound administered is effective to alleviate at
least one of the symptoms of the individual’s condition.
The lobeline compound can be administered alone, com

experiment. Data are presented as mean:S.E. fractional

release, Which represents the tritium in the superfusate

bined With an excipient, or coadministered With a second

sample as a percentage of the total tritium in the slice at the
time of sample collection. FIG. 2A illustrates the time course

drug having a similar or synergistic effect. The compound or

of the fractional release evoked by loW concentrations

60

composition is preferably administered subcutaneously,

(0.01—3 pM) of lobeline, and FIG. 2B illustrates that evoked

intramuscularly, intravenously, transdermally, orally,
intranasally, or rectally.
The utility of lobeline, analogs, and derivatives thereof,
e.g., those that form lobeline upon metabolism by the body,

by high concentrations (3—100 pM). *P<0.05, different from
65

basal out?oW; +P<0.05, different from the peak responses at
25 min for 0.01—3 pM and 30—300 pM; §P<0.05, different
from the peak responses of 0.01—10 pM and 100 pM;

6,087,376
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FIG. 8 depicts lobeline inhibition of [3H]DTBZ binding to

#P<0.05, different from the peak responses of 0.01—30 pM;
Fisher’s LSD post hoc test. n=6 rats.

rat striatal vesicles. Data represent the rneanzSEM prnol

FIG. 3 depicts the concentration-dependence of lobeline
evoked total [3H]over?oW from rat striatal slices preloaded
With [3H]DA. Data are presented as rnean:S.E. total [3H]

[3H]DTBZ bound/rng protein. Control represents the
amount of [3H]DTBZ bound in the absence of lobeline.

*p<0.05, signi?cantly different from control; Fisher least
signi?cant difference post hoc test. n=5 experirnents.

over?ow, Which represents the area under the curve of the
corresponding lobeline concentration-response as a function

FIG. 9 shoWs that d-arnphetarnine inhibits [3H]DTBZ

of time. The inset illustrates the total [3H]over?oW evoked

binding to rat striatal vesicles. Data represent the

by the loWer concentrations (0.01—1 nM) of lobeline. Con
trol slices Which Were superfused With buffer in the absence

10

release Was not different from basal during the course of

superfusion). *P<0.05, different from control and each of the
other lobeline concentrations; Duncan’s NeW Multiple
Range Test. n=6 rats.
FIG. 4 depicts the time course of the effect of rnecarny

rneanzSEM prnol [3H]DTBZ bound/rng protein. Control
represents the amount of [3H]DTBZ bound in the absence of
d-arnphetarnine. *p<0.05, signi?cantly different from con
trol; Fisher least signi?cant difference post hoc test. n=5

of lobeline did not evoke [3H]over?oW (i.e. fractional

experirnents.
15

FIG. 10 shoWs the time course of spontaneous [3H]DA
ef?ux frorn [3H]DA-preloaded striatal vesicles in the
absence of drug. Data are expressed as rneanzSEM [3H]DA

larnine to inhibit nicotine(10 nM)-evoked fractional release
of [3H]DA frorn preloaded rat stratal slices. For clarity of

ef?ux as a percent of total [3H]DA content of the vesicles at

graphical presentation, only signi?cant effects of the loWest
and highest concentration, 0.01 and 100 pM, respectively, of

time 0. n4 experirnents.

rnecarnylarnine are illustrated. Data are presented as
rnean:S.E. fractional release as percentage of basal out?oW.

FIG. 11 shoWs that d-arnphetarnine evokes [3H]DA
release from synaptic vesicles preloaded With [3H]DA.

Experiments were performed as described in Table 2 here
inbeloW. The time course begins at the time of nicotine (10

expressed as percent of control content. The total amount of

pM) addition to the superfusion buffer containing rnecarny

d-Arnphetarnine-evoked vesicular [3H]DA release Was
25

larnine. The control represents fractional release in the
absence of either rnecarnylarnine or nicotine in the super
fusion buffer. Duncan’s NeW Multiple Range Test revealed

[3H]DA present in control samples Was 4.37:1.06 prnol/rng
protein. *p<0.05, signi?cantly different from control; Fisher
least signi?cant difference post hoc test. n3 experirnents.

n=8 rats.

FIG. 12 depicts lobeline inhibition of nicotine-evoked
[3H]doparnine release from rat striatal slices. Striatal slices
Were obtained from rat brain, preincubated With [3H]

FIG. 5 depicts the effects of nicotine (0.01—1000 pM) and
lobeline (0.01—1000 pM) on rat striatal synaptosornal and

With Kreb’s buffer for 60 rnin. FolloWing the initial period

a signi?cant inhibitory effect of 0.01 pM rnecarnylarnine,
When the data Were collapsed across time of superfusion.

doparnine (0.1 nM) for 30 min and subsequently superfused
of superfusion, slices Were superfused With buffer contain
ing various concentrations of lobeline for 30 min and
subsequently various concentrations of nicotine Were
included in the buffer. Superfusate samples were collected to
determine the ability of lobeline to inhibit the nicotine
induced response.

synaptic vesicular [3H]DA uptake. III nicotine, synaptoso
rnal [3H]DA uptake; I nicotine, vesicular [3H]DA uptake; O
lobeline, synaptosornal [3H]DA uptake; O lobeline, vesicu
lar [3H]DA uptake. Data are presented as rnean:S.E. per

centage of total [3H]DA uptake. Total [3H]DA uptake for
synaptosornes and vesicles Was 10919.80 prnol/rnin/rng and

13401717 prnol/rnin/rng, respectively. Non-speci?c [3H]

40

FIG. 13 illustrates the current understanding of the pri

DA uptake in synaptosornal and vesicular experiments was
2% and 20%, respectively, of total [3H]DA uptake as deter
mined by incubation With 10 pM GBR and incubation at 0°

C., respectively. Experirnents examining the effect of nico
tine on synaptosornal uptake included a loW concentration
range (0.001—1 nM), hoWever, no effect Was observed and

rnary mechanism of the action of lobeline in the central
nervous system.
45

for clarity of graphical presentation these results are not

DETAILED DESCRIPTION OF THE
INVENTION

As used herein, the term “lobeline” refers to a compound

illustrated. *P<0.05, different from total [3H]DA uptake;

having the general chemical formula 2-[G-([3

Dunnett’s post hoc test. n=3—6 rats.

hydroxyphenethyl)-1-rnethyl-2-piperidyl]-acetophenone.

FIG. 6 depicts the endogenous DA and DOPAC
(dihydroxyphenylacetic acid) content in rat striatal slices

The term “lobeline” as used herein refers to the above
compound in its free form, or as a salt thereof, Which has the

superfused With high concentrations (30—100 nM) of

physiological activity addressed. Inasmuch as a compound

lobeline. Endogenous DA and DOPAC content Were deter

mined after 60 rnin superfusion With various concentrations
of lobeline. Data are presented as rnean:S.E. ng/rng protein.

having this formula has three chiral centers, eight optical
55

*P<0.05, different from control, P<0.05, **P<0.001, differ

mentioned.

ent from control; Dunnett’s post hoc test. n=8 rats.

FIG. 7 depicts equilibrium binding of [3H]DTBZ to rat
striatal vesicles. Striatal vesicles Were incubated for 10 min

60

at 25° C. in the absence and presence of [3H]DTBZ (0.5—10

nM) Nonspeci?c binding (0) was determined using 20 pM

of the piperidinyl group in the lobeline rnolecule.

betWeen total binding (not shoWn) and the nonspeci?c
ing data from the saturation analyses. n=4 experiments.

The term “lobeline analogs” and equivalents thereof, as
used herein, refers to chemical derivatives of lobeline, such
as those obtained by oxidation or reduction of lobeline,
others obtained by esteri?cation of lobeline and its redox
derivatives, as Well as various substitutions at the N-position

TBZ. Speci?c binding (O) Was de?ned as the difference

binding. Data are rneanzSEM prnol/rng protein. Inset: Scat
chard transformation of the mean speci?c [3H]DTBZ bind

isomers of the compound can exist. HoWever, particular
optical isorner(s) are not intended herein unless speci?cally
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Preferred lobeline analogs, Which may act as prodrugs of

lobeline itself When metabolized by the body, include those

contemplated by formula (I) (Without regard to chirality):

6,087,376
8
Apharmaceutical composition containing a lobeline com
pound of the invention is also contemplated, Which may

(I)

include a conventional additive such as a stabiliZer, buffer,

salt, preservative, ?ller, ?avor enhancer, and the like, as
knoWn to those skilled in the art. Representative buffers

include phosphates, carbonates, citrates, and the like. Exem

plary preservatives include EDTA, EGTA, BHA, BHT, and
the like.

A composition of the invention may be administered by
10

lotion; orally, i.e., in solid or liquid form (tablet, gelcap, time
release capsule, poWder, solution, or suspension in aqueous

Where R1 and R2 each independently represents hydrogen,
loWer alkyl, loWer alkenyl, loWer alkylcarbonyl,
arylcarbonyl, e.g., phenylcarbonyl, aralkylcarbonyl, e.g.,
alkylphenylcarbonyl, loWer alkoxycarbonyl, loWer

alkylaminocarbonyl, higher alkylcarbonyl, and poly
(alkyleneoxide)carbonyl; R3 and R4 each independently

or non-aqueous liquid); intravenously as an infusion or

injection, i.e., as a solution, suspension, or emulsion in a
15

loWer alkyl. Whenever a carbonyl-containing substituent is
provided as R1 or R2, it is understood that the carbonyl group
is covalently bonded to the respective O atom appearing in

a transdermal patch; rectally, as a suppository, and the like.

per day. The amount to be administered depends to some

extent on the lipophilicity of the speci?c compound selected,
since it is expected that this property of the compound Will
cause it to partition into fatty deposits of the subject. The

Thus, in the instances Where the substituent is an

alkoxycarbonyl or alkylaminocarbonyl, a carbonate or car

bamate linkage is present in the molecule.
Preferred substituents for R1 and R2 include methylcar

bonyl (acetyl), phenylcarbonyl (benZoyl), natural fatty acid
groups, e.g., palmitoyl, oleyl, linoleyl, stearyl, and lauryl,

pharmaceutically acceptable carrier; transdermally, e.g., via
Generally, it is expected that a pharmacologically effec
tive dose of a present compound Will require its adminis
tration in an amount less than 1x10‘3 mg/kg of body Weight

represents hydrogen or combines With R1 and
,
respectively, to form a double bond; and X represents H or

formula

inhalation, i.e., intranasally as an aerosol or nasal formula
tion; topically, i.e., in the form of an ointment, cream or

precise amount to be administered can be determined by the
25

and polyethyleneglycol (PEG) covalently bonded to the

skilled practitioner in vieW of desired dosages, side effects,
the medical history of the patient, and the like. It is antici
pated that the compound Will be administered in an amount

ranging from about 1x10“5 to about 1x10“3 mg/kg/day.

molecule via a carbonate linkage. Long chain moieties such

The present study Was performed to determine the

as a PEG group in a lobeline prodrug enhance transdermal

involvement of nicotinic receptors in lobeline-evoked [3H]
over?oW from rat striatal slices preloaded With [3H]DA. The
calcium-dependency of the effect of lobeline and the ability

delivery of the molecule, Which may be metaboliZed to
lobeline and derivatives thereof.
As used herein, the terms “loWer alkyl”, “loWer alkenyl”,
“loWer alkoxy”, and the like, refer to normal, branched and
cyclic hydrocarbyl groups containing 1 to 6 carbon atoms.

of mecamylamine to inhibit the lobeline response Were
determined. To assess the contribution of potential effects on

The term “higher alkyl” includes alkyl groups containing 7

DA uptake, the effect of nicotine and lobeline to inhibit

to about 20 carbon atoms. The term “aryl” refers to a 35 [3H]DA uptake into striatal synaptosomes and synaptic
vesicle preparations Was also determined. Based on the
hydrocarbon group containing one or more aromatic rings,
present results of the in vitro superfusion studies, striatal
optionally substituted With one or more heteroatoms. The

dopamine (DA) and dihydroxy phenylacetic acid (DOPAC)

term “aralkyl” refers to an aryl group covalently bonded to
a loWer alkyl group.

content Were also determined after lobeline superfusion in

having the above formula may be converted into a different

vitro, and after lobeline administration in vivo.
Effect of Nicotine on Superfused Rat Striatal Slices Pre

molecule upon metabolism by the body. For example, When

loaded With [3H]DA.

ever an acetyl group is present at R1 and/or R2 in the

In a concentration-dependent manner, nicotine evoked an
increase in the fractional release of tritium over the time

It is, of course, contemplated that certain lobeline analogs

compound, the acetyl group may be removed by metabolic

course of the superfusion experiment (FIG. 1A). Repeated

processes, e.g., such as occur in the gastrointestinal tract or

the liver. The choice of substituents is subject to consider

45

ations of toxicity, side effects, dosage, and the like.
Particularly preferred lobeline analogs are those in Which
(i) both R1 and R2 are H (i.e., a lobelanidine compound), (ii)

(F10)429)=9.76, P<0.0001), but the concentration><time inter
action Was not signi?cant (F(8O)42O)=1.22, P>0.05). Frac

either R1 or R2 is H and the other combines With R3 or R4
to form a double bond (i.e., a lobeline compound), and (iii)
both R1 and R2 combine With either R3 or R4 to form a
double bond (i.e., a lobelanine compound). It is also pre
ferred that X in the above formula represents a methyl

group. Preferably, the chirality at the 2 and 6 positions of the
piperidyl ring of the compounds is the same as in naturally

occurring lobeline.

measures, tWo-Way AN OVA (analysis of variants) revealed
a signi?cant main effect of nicotine concentration (F(8>429)=
29.45, P<0.0001) and a signi?cant main effect of time

55

tional release peaked Within 10—15 min after the addition of
nicotine to the superfusion buffer. From 10—25 min after the
addition of nicotine, fractional release Was signi?cantly
increased above basal out?oW, When the data Were collapsed
across nicotine concentration. At peak fractional release, the
highest concentration of nicotine examined increased frac
tional release 2-fold above basal. Furthermore, When the

in its free base form or as a soluble salt. Whenever it is

data Were collapsed across nicotine concentration, fractional
release, from 30—45 min after nicotine addition, Was not

desired to employ a salt of lobeline or analog, it is preferred
that a soluble salt be employed. Some preferred salts include

signi?cantly different from basal, despite the presence of
nicotine in the superfusion buffer throughout the superfusion

the hydrochloride, hydrobromide, nitrate, sulfate, tartrate,
fumarate, citrate, maleate, ascorbate, lactate, aspartate,

period.

Lobeline, as Well as analogs thereof, can be administered

Presentation of the results as nicotine-evoked total [3H]
over?oW accentuates the concentration-dependent nature of

mesylate, benZene sulfonate, propionate and succinate salts.
Also, other anionic moieties such as fatty acid salts can be

the response to nicotine (FIG. 1B). Repeated-measures,

used, e.g., palmitate salt.

one-Way ANOVA revealed a signi?cant nicotine

As used herein, an “effective amount”, and similar usages,

65

concentration effect (F(8)39)=25.77, P<0.0001). The loWest

refers to an amount of a drug effective to reduce an indi

nicotine concentration Which evoked a signi?cant increase

vidual’s desire for a drug of abuse, or for food.

in [3H]over?oW Was 0.05 pM. A plateau in the

6,087,376
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10

concentration-response curve was not apparent over the

concentration range examined. Higher concentrations of

TABLE 1

nicotine were not examined because of the extensive work

of Westfall and collaborators (Westfall, 1974; Westfall et al.,

Lobeline Evokes [3H] Over?ow from Rat Striatal Slices Preloaded
with [3H] DA in a Calcium Independent Manner"

1987) indicating that nicotine concentrations higher than100
pM act to release DA from superfused rat striatal slices by

Lobeline
Concentration

a mechanism which is not calcium-dependent nor nicotinic

receptor mediated.
Effect of Lobeline on Superfused Rat Striatal Slices Pre

loaded with [3H]DA.
Lobeline evoked a marked concentration-dependent

10

increase in fractional release of tritium over the time course

of the superfusion experiment (FIG. 2). Repeated-measures,

In a concentration-dependent manner, mecamylamine sig

ni?cantly inhibited nicotine (10 pM)-evoked [3H]over?ow

during the entire superfusion period. Lobeline (3 pM)

from rat striatal slices preloaded with [3H]DA (See Table 2).
20

Repeated-measures, one-way AN OVA revealed a signi?cant

mecamylamine concentration effect (F(5>38)=4.46, P<0.005).
Concentrations of mecamylamine from 0.1—100 pM inhib
ited (57%—5 91%) the effect of nicotine to evoke [3H]

evoked by high concentrations (10—100 pM) of lobeline was
25

over?ow.
The time course of the effect of mecamylamine illustrates
the pattern and the extent of the inhibition of the nicotine

evoked increase in fractional release (FIG. 4) Repeated

Of note is the magnitude of the response to lobeline in

peak fractional release induced by the highest concentration
(100 pM) of nicotine was only 2% of total tritium in the

Nicotine-Evoked and Lobeline-Evoked [3H]Over?ow:

Mecamylamine Antagonism.

lobeline did not signi?cantly increase fractional release

comparison to that observed after superfusion with nicotine.
Peak fractional release after superfusion with 30 and 100 pM
lobeline was approximately 15% and 30%, respectively, of
the total tritium present in the striatal slice (FIG. 2B).
Furthermore, over the remainder of the superfusion period,
fractional release in superfusate samples continued to be
10—20% of the total tritium in the slice. On the other hand,

0 z 0
2.9 r 0.2
45.0 r 4.2
185.0 1 12.0

Data are presented as mean 1 SE. total [3H] over?ow, n = 6 rats/group.

15

a signi?cant concentration><time interaction (FOO)36 =

signi?cantly increased 10 min after the addition of lobeline
to the buffer and remained signi?cantly higher than basal
until the end of the experiment.

0.6 r 0.4
2.0 r 0.6
31.9 r 2.2
198.0 1 20

Krebs’ buffer or calcium-free buffer with the addition of 0.5 mM EGTA.

44.85, P<0.0001). Low concentrations (0.01—1 pM) of
evoked a signi?cant increase in fractional release 15 and 20
min after its addiction to the buffer. Subsequently, the
fractional release returned towards basal, despite the con
tinuous presence of lobeline in the buffer. Fractional release

Calcium-Free Buffer

*Concentration-response of lobeline was determined using either control

two-way AN OVA revealed a signi?cant main effect of

lobeline concentration (F7)363=1057.13, P<0.0001), a sig
ni?cant main effect of time (F1O)363)=132.24, P<0.0001) and

0.1
1
10
100

Control Buffer

measures, two-way AN OVA revealed a signi?cant main

effect of mecamylamine concentration (F 6>599)=19.59,
30

P<0.0001), a signi?cant main effect of time ( (11)599)=4.98,
P<0.0001), but the concentration><time interaction was not

signi?cant (F(66>599)=0.97, P>0.05). When the data were

35

collapsed across time, the lowest concentration of mecamy
lamine to produce a signi?cant inhibition of nicotine’s effect
was 0.01 pM. The time course illustrates the small, but

signi?cant, inhibition (36%) of nicotine’s effect produced by

revealed a concentration-dependent effect of lobeline and a

this low concentration of mecamylamine. Interestingly, the
inhibitory effect of 0.01 pM mecamylamine was not detected
when the results were expressed as total [3H]over?ow (See
Table 2). The maximal inhibitory effect of the highest
concentration (100 pM) of mecamylamine is also illustrated
in FIG. 4 for comparison.

marked increase in [3H]over?ow evoked by high concen
trations of lobeline (FIG. 3). Repeated-measures, one-way

TABLE 2

slice, and fractional release returned to basal during the

course of the experiment (FIG. 1A). These results suggest
the potential for depletion of DA storage pools following
superfusion with lobeline at high concentrations.
Expression of the results as total [3H]over?ow also

40

AN OVA revealed a signi?cant lobeline concentration effect

(F(6)35)=61.55, P<0.0001). The lowest concentration of

45

Mecamylamine Inhibition of Nicotine(10 ,uM)-evoked [3H] Over?ow
from Rat Striatal Slices Preloaded with [3H] DA"

lobeline to evoke a signi?cant increase in total [3H]over?ow
was 1 pM. As the lobeline concentration was increased, a

Mecamylamine

Total [3H] Over?ow

signi?cantly greater total [3H]over?ow was evoked.
Furthermore, a plateau in the concentration-response curve
was not apparent over the concentration range examined.

50

Lobeline-induced [3H]over?ow: Lack of Calcium

Dependency.
Previous studies (Westfall, 1974; Westfall et al., 1987)

reported that nicotine (<100 pM)-evoked [3H]over?ow from
rat striatal slices preloaded with [3H]over?ow was calcium
dependent. In order to determine if lobeline-induced [3H]

0
0.01
0.1
1
10
100

5.60
3.57
2.40
1.59
1.02
0.54

r
r
r
r
r
r

1.20
1.52
0.87"
0.64**
0.43**
0.32**

*Slices were superfused with buffer in the absence or presence of
55 mecamylamine (0.01-100 ,uM)for 60 min, followed by 60 min superfusion
with the addition of 10 ,uM of nicotine to the buffer containing the various

over?ow was calcium-dependent, the effect of lobeline was

concentrations of mecamylamine. Data are presented as mean : S.E. total

determined in a calcium-free superfusion buffer containing

[3H] over?ow. Total [3H] over?ow for slices superfused in the absence of

0.5 mM EGTA (ethylene glycol-bis([3-aminoethyl ether)-N,
N,N‘,N‘-tetraacetic acid (See Table 1). Two-way ANOVA

any drug was 0.06 r 0.06. Slices superfused with nicotine (10 ,uM) in the
absence of mecamylamine were considered control for statistical analysis.
60 *P < 0.05, one-tailed, different from control; *"P < 0.05, two-tailed, differ

revealed a signi?cant main effect of lobeline concentration

ent from control; Dunnett’s post hoc test. n = 8 rats.

(within-group factor, F(3>39)=473.08, P<0.001), however, the

The ability of mecamylamine (1—100 pM) to inhibit
lobeline(0.1—100 pM)-evoked total [3H]over?ow is shown

main effect of inclusion of calcium in the buffer was not

signi?cant (between-groups factor, F(1>39)=0.13, P>0.05)
and the interaction term also was not signi?cant (F(3)39)=

1.64, P>0.05). Thus, the effect of lobeline on [3H]over?ow
was not altered-following removal of calcium from the

superfusion buffer.
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in Table 3. Concentrations of mecamylamine which signi?
cantly inhibited nicotine-evoked [3H]over?ow were utiliZed
in these experiments. The effect of lobeline (0.1—100 pM) in
the absence of mecamylamine represented control. Two-way

6,087,376
11

12

AN OVA revealed a signi?cant main effect of lobeline con

tion of tetrabenaZine which signi?cantly inhibited vesicular
uptake was 0.07 nM. Complete inhibition was obtained at 1
pM tetrabenaZine. Thus, lobeline was approximately one
order of magnitude less potent than tetrabenaZine in inhib

centration (within groups factor, F(4)56)=603.84, P<0.0001);
however, both the main effect of mecamylamine concentra

tion (between-groups factor, F(3)14)=2.79, P>0.05) and the
lobeline><mecamylamine interaction were not signi?cant

iting vesicular [3H]DA uptake.

(F(12)56)=1.30, P>0.05). Thus, lobeline-evoked [3H]over?ow

Effect of Lobeline on Endogenous DA and DOPAC Content
in Rat Striatum.
The marked increase in [3H]over?ow in response to

was not inhibited by mecamylamine.
TABLE 3
Lobeline-evoked [3H] Over?ow from Rat Striatal Slices Preloaded
with [3H] DA is Not Inhibited bv Mecamvlamine"

10

myla
mine Con

15

Lobeline Concentration (MM)

tion (MM) 0.1

1

3

10

10.3 r 0.8
10.8 r 1.4
8.2 r 1.5
6.5 r 0.9

31.9
32.5
41.0
20.0

and vesicular [3H]DA uptake (FIG. 5) suggested that super
fusion with lobeline may deplete striatal DA content. One
way ANOVA revealed a signi?cant lobeline concentration

Meca

centra-

superfusion with high concentrations of lobeline (FIGS. 2
and 3) and the lobeline-induced inhibition of synaptosomal

effect on DA (F(6>41)=15.35, P<0.0001) and DOPAC (F(6)
40)=6.90, P<0.0001) content in superfused striatal slices.
Superfusion with low concentrations (0.1—10 nM) of
lobeline did not alter DA or DOPAC content (data not

100

shown); however, when slices were superfused with high
0
1
10
100

0.6
0.9
0.8
0.5

r
r
r
r

0.4
0.5
0.3
0.4

2.0
4.9
2.4
0.7

r
r
r
r

0.6
1.8
0.5
0.1

r
r
r
r

2.2
1.0
6.2
2.0

185.0
180.0
179.5
160.4

1
1
1
1

12
47.6
12.2
30.2

lobeline concentrations (30—100 pM), lobeline signi?cantly
20

*Slices were superfused with buffer in the absence or presence of

DA content occurred after in vivo administration of lobeline

mecamylamine (1-100 ,uM) for 60 min, followed by 60 min superfusion
with the addition of lobeline (0.1-100 ,uM) to the buffer. Data are pre
sented as mean : S.E. total [3H] over?ow. n = 4-6 rats.

25

The Effect of Nicotine and Lobeline on [3H]DA Uptake Into
Rat Striatal Synaptosomes and Synaptic Vesicles.
To determine if modulation of DA uptake contributed to
the increase in [3H]over?ow evoked by nicotine or lobeline,

[3H]DA uptake into striatal synaptosomes and synaptic

30

vesicles was determined (FIG. 5). Nicotine did not inhibit
[3H]DA uptake into striatal synaptosomes over the concen

tration range (0.001 nM—100 ,uM) examined. Before deter
mining the effect of nicotine on synaptic vesicular [3H]DA
uptake, the purity of the isolated synaptic vesicle preparation
was determined by electron microscopy of representative
vesicle preparations. Plain spheroid or ellipsoid synaptic

depleted endogenous DA content and increased DOPAC
content compared to a control (FIG. 6).
To determine if lobeline-induced depletion of endogenous

to rats, lobeline was administered (s.c.) acutely (0, 1, 3, 10,
30 mg/kg), intermittently (0, 3, 10 mg/kg, once daily for 10
days) or continuously (0, and 30 mg/kg, by osmotic
minipump delivery for 21 days), and rat striata were
obtained for the determination of endogenous DA and
DOPAC content (See Table 4). Two-way AN OVA revealed
that lobeline did not signi?cantly alter either striatal DA

(F(4)58)=0.05, P>0.05) or DOPAC (F(4)58)=0.54, P>0.05)
content. Therefore, lobeline administration in vivo did not
deplete striatal DA content at any dose of lobeline or any

treatment regimen examined.
35

TABLE 4
In vivo Administration of Lobeline Does Not Alter DA and DOPAC
Content in Rat Striatum"

vesicle pro?les of approximately 50 nm in diameter were the

predominant membrane structures observed. Very few

(2 1%) contaminating membrane fragments were present.

Lobeline (mg/kg)

40

The effect of nicotine on [3H]DA uptake into synaptic
vesicles was analyZed by repeated-measures, one-way
DA

AN OVA which revealed a signi?cant nicotine concentration

effect (F9>28=3.30, P<0.05). However, Dunnett’s post hoc
analysis revealed that signi?cant inhibition of uptake only

Inter-

Chronic

30

841 z 76

665 z 126

743 z 57

ND

778 z 27

800 z 41

ND

840 z 72

ND

ND

ND

856 z 144

Acute

84 z 12

81 z 12

89

Inter-

63 z 6

ND

57 _ 12

15

57 + 3

82

8

72 z 10
ND

61 r 4

ND

ND

ND

62 r 10

mittent
50 Chronic

*Rat striata were obtained 1 hr after acute lobeline administration (0, 1—30

in the synaptosomal preparation was 30 nM. The IC5O for

mg/kg, s.c.); after intermittent lobeline administration (0,3 and 10 mg/kg,
once daily injection for 10 days, s.c.); and after chronic lobeline delivery
by osmotic minipump (0 and 30 mg/kg/day for 21 days, s.c.). Data are

lobeline to inhibit uptake into synaptosomes was 80:12 pM.
Moreover, in contrast to nicotine, lobeline potently inhibited

55 presented as mean : S.E. ng/mg protein. ND: not determined. n = 6-8

rats/group.

[3H]DTBZ Binding
Equilibrium binding analysis was performed to determine
the values of KD and Bmax for [3H]DTBZ binding to rat
60

striatal vesicle membranes. Results revealed that the speci?c

binding of [3H]DTBZ was saturable and represented
60—80% of total binding of all [3H]DTBZ concentrations

[3H]DA uptake. TetrabenaZine (0.001—100 pM), a high
af?nity and speci?c inhibitor of the synaptic vesicular
monoamine transporter (VMAT2), signi?cantly inhibited
striatal vesicular [3H]DA uptake in a concentration

10

761 z 103

DOPAC

concentration of lobeline to produce a signi?cant inhibition

centration of lobeline to produce a signi?cant inhibition was
0.3 pM, and complete inhibition was obtained at 10 nM. The
IC50 value for lobeline to inhibit vesicular uptake was
0.88:0.001 pM, which was 2-orders of magnitude lower
than that for lobeline-induced inhibition of synaptosomal

3

756 z 111

45 mittent

measures, one-way AN OVA revealed a signi?cant lobeline

[3H]DA uptake into synaptic vesicles in a concentration
dependent manner (F8)26=28.60, P<0.0001). The lowest con

1

739 z 64

Acute

occurred at very high concentration (1 mM) of nicotine.
Lobeline inhibited [3H]DA uptake into synaptopsomes in
a concentration-dependent manner (FIG. 5). Repeated

concentration effect (F9)38=154.0, P<0.0001). The lowest

0

(0.5—10 nM) examined (FIG. 7). Speci?c [3H]DTBZ bind
ing reached a plateau at a concentration of 3 nM. Nonspe
65

ci?c binding increased linearly as a concentration of [3H]

dependent manner (F(9)28)=23.78, P<0.0001). The IC5O for

DTBZ increased. Scatchard analysis of the speci?c [3H]

tetrabenaZine was 77.7113 nM, and the lowest concentra

DTBZ binding revealed a KB of 1.67 nM and a Bmax of 8.68

